HCA Beats Q3 Estimates but Payer Mix Shift Costs $400 Million in Quarter

HCA Healthcare delivered a third-quarter beat that initially pleased investors, then unsettled them once management detailed just how much of that outperformance is being offset by structural payer mix problems that show no sign of resolving soon.

The country's largest for-profit hospital operator posted Q3 revenue of $19.85 billion and earnings of $7.22 per diluted share, both ahead of consensus and ahead of the same quarter last year. Shares opened roughly 4% higher Tuesday morning. That optimism did not survive the earnings call. By noon, HCA stock had reversed to trade more than 4% below the open, a swing that tells you more about investor concerns than the headline numbers do.

The operational story behind the beat is genuinely strong. Same-facility admissions rose 2.7% year over year, adjusted same-facility admissions climbed 3%, and same-facility emergency room visits jumped 5.1%. CEO Sam Hazen framed this as evidence of the company's durability. "HCA has strong staying power because of our scale, the important role we play in providing critical services to communities and our disciplined culture," he told analysts on the call.

Cost control backed up the volume story. Same-facility cost per equivalent admission was flat year over year, a notable achievement in an inflationary labor environment. Executives also booked about $50 million of incremental net benefit from Medicaid supplemental payment programs in the quarter, putting the full-year figure on pace for $600 million to $800 million.

The Payer Mix Problem Isn't Going Away

None of that operational strength changes the underlying math on coverage losses. HCA continues to see patients who drop off ACA exchange plans migrate "almost one-for-one into uninsured" status, according to CFO Mike Marks. Uninsured volumes climbed from 8.5% of total equivalent admissions in 2025 to 10.5% this year. That shift alone cost HCA an estimated $400 million in adjusted EBITDA during the quarter.

The full-year impact is now tracking at or slightly above the top of management's previously updated guidance range. Hazen was candid about the magnitude, conceding the exchange disruption "was a little bit higher than we estimated." Exchange volumes did improve roughly 8% from the second quarter, offering a sliver of good news, but the structural dynamic between subsidy loss and coverage churn remains intact.

Elective surgery is the other soft spot. Same-facility inpatient surgery fell 1.4% year over year while outpatient surgery dropped 3.7%. Marks described "solid growth" in emergent procedures, but affordability concerns and coverage losses are suppressing discretionary volume. That combination, weaker payer mix plus softer elective demand, held same-facility revenue per equivalent admission to just 0.6% growth for the quarter. Professional fees rose 12% and remain, in Marks' words, "a pressure point for the company."

Layer in policy risk and the picture gets more complicated. Medicaid changes tied to the One Big Beautiful Bill Act are expected to cut HCA's supplemental payment net benefit by $550 million to $650 million next year. Management expects its resiliency program and projected volume growth of 2% to 3% to offset much of that hit, but the arithmetic leaves little room for error.

Hazen's guidance for 2027 was deliberately unspecific: earnings will be "generally consistent with 2026." That is not a growth forecast. It is a statement that HCA expects to tread water while absorbing fresh Medicaid headwinds, with performance only returning to the company's long-term growth targets sometime beyond next year. Analysts on the call pushed for firmer numbers and got little. Executives repeatedly pointed back to the third quarter's trajectory as the basis for confidence, while acknowledging they want to see fourth-quarter trends and open enrollment results before committing to anything more concrete.

Three assumptions underpin the 2027 outlook, and each carries its own risk. Hazen said the company believes the worst of exchange enrollment disruption has already passed through the payer mix. He also assumed no material policy changes beyond the OBBBA, a bet on a quiet legislative environment that may or may not hold. And he is counting on internal initiatives around cost reduction, technology and network development to deliver as planned. Any one of those assumptions breaking the wrong way would pressure the "consistent with 2026" framing.

HCA declared a quarterly cash dividend of $0.78 per share, a modest but steady signal of capital discipline amid the uncertainty. For full-year 2025, the company grew revenue 7.1% to $75.6 billion and reported $6.8 billion in net income, underscoring the scale advantage that management keeps citing as its buffer against policy shocks.

HCA is the first major for-profit operator to report this earnings season, with Tenet Healthcare, Universal Health Services and Community Health Systems set to follow later this week. Their results will show whether HCA's experience, strong underlying demand offset by exchange churn and soft elective volumes, is an industry-wide pattern or a company-specific story shaped by HCA's particular market footprint.

What Investors Should Watch

The quarter confirms that demand for hospital services remains robust and that HCA's cost discipline is real. But the $400 million quarterly hit from payer mix shift is not a one-time item, it is a trend line that management itself expects to persist, just at a slightly lower magnitude, into next year. Investors should watch fourth-quarter volume data and open enrollment outcomes closely, since those are the two variables management explicitly flagged as prerequisites for a firmer 2027 outlook. The stock's intraday reversal suggests the market is already pricing in skepticism about how cleanly HCA can execute its resiliency program against a backdrop of Medicaid funding cuts and uncertain exchange enrollment. Scale and discipline have carried HCA through 2026. Whether they are enough to produce actual growth, rather than flat performance, in 2027 remains the open question.